Morningside Pharmaceuticals Limited
- Active
- Large
- 34 years
- 93 employees
- £46,217,035 (cur assets)
- Regular importer
- Regular exporter
- Virtual address
- 4 directors
- No owners
- Northampton
- Rating 3.0 (2)
Two conditions of three:
1.Turnover > £36 million
2.Balance sheet total > £18 million
3.Average number of employees > 250
The directors list was changed 3 months ago, a good sign to sell them something.
Field of Operation
Website
Social media
Summary
Morningside Pharmaceuticals Ltd from Northampton UK: a large company with an active status, founded 33 years ago, employs 102 people, and holds £44,284,128 in assets. It operates from a virtual address, managed by six directors, and curiously, has no officially declared owners. Its Google rating is a modest 3.0 based on just two reviews, and it regularly imports and exports pharmaceutical products—172 months of importing and 204 months of exporting, respectively.
The company's website positions Morningside Pharmaceuticals as a manufacturer, wholesaler, distributor, and supplier of high-quality generic branded medicines and healthcare products, both in the UK and for export markets. It highlights awards and recognition, including partnerships with organizations like the British Science Festival and sponsorship of the Morningside Arena. The website also showcases its commitment to international trade, with endorsements from former Prime Minister Theresa May and former Secretary of State for International Trade Dr Liam Fox.
Financially, Morningside Pharmaceuticals appears to be navigating some shifts. Accrued liabilities and deferred income increased by 42%, while cash and cash equivalents surged by 190%, reaching £5,700,000. However, director remuneration benefits decreased significantly, dropping 60% to £380,000. Turnover remained stable at £57,000,000, but net assets grew substantially by 110% to £28,000,000. The company's workforce has slightly decreased, with the average number of employees dropping from 100 to 93. It's worth noting that the company’s financial statements were audited by TC Group.
The company’s large size—meeting two of three criteria for being a large company—suggests a robust operation. The increase in liabilities, however, could indicate increased borrowing or extended payment terms with suppliers. The decrease in employee numbers might reflect restructuring or automation efforts. Overall, Morningside Pharmaceuticals appears to be a stable, established player in the pharmaceutical industry, though it’s worth keeping an eye on its balance sheet to see if the increased liabilities are a long-term concern.
Registered in England/Wales under the registration number 02672877, with a registered address at NN4 7YB, England, Northampton, Nene House, 4 Rushmills.
WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.
Managers
-
Individual
- 2 years
- 12
-
Resident of United Kingdom
-
Individual
- 2 years
- 12
-
Resident of United Kingdom
-
Corporate
- 3 years
- 119
-
Resident of United Kingdom
-
Individual
- 3 years
- 8
-
Resident of United Kingdom
Last reports
The latest confirmation statement submitted eleven months ago.
Last news
-
Termination of appointment of Timothy James Brady as a director on 2025-10-31Download 1 page pdf report
-
Termination of appointment of Clifford Roy Fung as a director on 2025-10-31Download 1 page pdf report
-
Full accounts made up to 2024-12-31Download 38 pages pdf report
Importer profile by HS codes
Click on the map to see detailed UK statistics on HS code, including companies list.
Last imported products
Click on items to see detailed UK statistics on HS code, including companies list.
Exporter profile by HS codes
Click on the map to see detailed UK statistics on HS code, including companies list.
Last exported products
Click on items to see detailed UK statistics on HS code, including companies list.
FAQ about Morningside Pharmaceuticals Limited
Looking for leads in the UK?
Try our FREE App—access UK datasets with limited features!